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Background The current lifetable approach to survival
estimation is favoured by CF registries. Recognising the
limitation of this approach, we examined the utility of
a parametric survival model to project birth cohort
survival estimates beyond the follow-up period, where
short duration of follow-up meant median survival
estimates were indeterminable.
Methods Parametric models were ﬁtted to observed
survivorship data from the US CF Foundation (CFF)
Patient Registry 1980e1994 birth cohort. Model-
predicted median survival was estimated. The best ﬁtting
model was applied to a Cystic Fibrosis Registry of Ireland
dataset to allow an evaluation of the model’s ability to
estimate predicted median survival. This involved
a comparison of birth cohort lifetable predicted and
observed (KaplaneMeier) median survival estimates.
Results A Weibull model with main effects of gender
and birth cohort was developed using a US CFF dataset
(n¼13115) for which median survival was not directly
estimable. Birth cohort lifetable predicted median survival
for male and female patients born between 1985 and
1994 and surviving their ﬁrst birthday was 50.9 and
42.4 years respectively. To evaluate the accuracy of
a Weibull model in predicting median survival, a model
was developed for the 1980e1984 Cystic Fibrosis
Registry of Ireland birth cohort (n¼243), which had an
observed (KaplaneMeier) median survival of 27.7 years.
Model-predicted median survival estimates were
calculated using data censored at different follow-up
periods. The estimates converged to the true value as
length of follow-up increased.
Conclusions Accurate prognostic information that is
clinically critical for care of patients affected by rare, life-
limiting disorders can be provided by parametric survival
models. Problems associated with short duration of
follow-up for recent birth cohorts can be overcome using
this approach, providing better opportunities to monitor
survival and plan services locally.
INTRODUCTION
Cystic ﬁbrosis (CF) registries are the principal
source of data for analysis of CF survival.
1 The US
CF Registry is one of the largest and longest
established, reporting data from over 25000
patients receiving care at CF Foundation (CFF)
accredited centres since 1982. Median survival is
a common measure used by registries to monitor
life expectancy for patients with CF. Median
survival estimation follows an entire CF population
until half are deceased, and is the age at which half
of the population have died. Median survival can be
derived using two different approaches: current
(period) and cohort lifetables.
2e8 However, the
application of each has limitations in CF
9 and has
resulted in failure to adopt a simple standardised
approach internationally.
The current lifetable approach takes age-speciﬁc
mortality rates observed in a calendar year and
estimates a ‘current lifetable predicted median
survival’ for a hypothetical population by assuming
those mortality rates validly estimate future rates
and remain constant over the population’s life-
time.
10 However mortality rates are not static;
notable improvements have been observed during
childhood in recent years.
91 1
The alternative method uses a birth cohort
lifetable to estimate ‘birth cohort lifetable observed
median survival’ and requires all CF births in
a given period to be identiﬁed and followed until
death or until more than 50% are deceased for
estimation of median survival. Cohorts of recent
births will not have an estimate for many years
because more than half are still alive.
12
Because of the inability of many CF registries to
observe birth cohort lifetable median survival for
Key messages
What is the key question?
Can median survival estimates be projected beyond
observed survivorship data for recent birth cohorts
of people with cystic ﬁbrosis (CF) when more than
half of the cohort is still alive?
What is the bottom line?
Parametric modelling of CF birth cohort data can
overcome the challenge of estimating birth cohort
median survival following a short follow-up period.
Why read on?
Accurate prognostic information can be provided by
parametric models of CF birth cohort data,
providing better opportunities to monitor and plan
CF services.
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Cystic ﬁbrosiscohorts of recent births, the current lifetable approach is more
frequently applied to monitor temporal trends in median
survival.
3 4 For instance, in 2008, the US CFF Patient Registry
reported that 46.3% of patients with CF were aged $18 years,
3
and that the current lifetable predicted median survival estimate
was 37$4 years.
We examined the utility of a parametric survival model to
obtain estimates of birth cohort lifetable predicted median
survival beyond the follow-up period, where short duration of
follow-up by CF registries meant birth cohort lifetable observed
median survival estimates were otherwise indeterminable.
STUDY DATA
This analysis is based on CF data from two patient registries.
The ﬁrst dataset was derived from the US CFF Patient Registry.
This registry conﬁrms deaths and death dates by direct contact
with the CF centres. US death certiﬁcation records were
unavailable and patients lost to follow-up in 2007 (did not
attend a CFF clinic in that year) were therefore excluded from
this analysis. The second dataset was deﬁned using data from
the Cystic Fibrosis Registry of Ireland (CFRI) and a listing of
deaths compiled from three sources: Central Statistics Ofﬁce
registered deaths when CF was reported as the underlying cause
(1980e2007), CF centre records of CF deaths (2002e2007), and
CF patient association recorded deaths (1986e2007). Study
patients not reported as deceased were therefore presumed to be
alive.
Each study population comprised a birth cohort of patients
with CF born between 1980 and 1994 and diagnosed by 31
December 2007 (‘study end date’). Patients who underwent
solid-organ transplantation were not excluded or censored at
transplantation to ensure consistency across datasets. The
following data were provided for each patient: year of birth,
gender, vital status on study end date, and survival time from
birth to death or study end date. We calculated survival for all
study patients from date of birth, although left truncation at
either date of diagnosis or entry into the CF registry would be
the most appropriate treatment of the data. Left truncation was
precluded by the absence of date of diagnosis data for Ireland
decedents not enrolled on the CFRI (ie, study patients identiﬁed
from registered death records). Although the US and Irish CF
registries report the highest CF population ascertainment rates
internationally (approximately 90%), median survival estimates
may be unavoidably biased because all people with CF born in
a speciﬁc time period may not have been detected and followed
over the period.
13
Table 1 shows differences between CFF and CFRI birth
cohorts. The number of US registry-enrolled patients with CF
born between 1980 and 1994 is 20 times that of the Irish
registry, and the number of birth cohort deaths by 2007 is nearly
twice as many for CFRI (30.2%) compared with CFF (17.4%).
Deaths in CFF and CFRI birth cohorts were then examined
using three, 5-year birth cohorts (1980e1984, 1985e1989,
1990e1994) (table 2). Such a small proportion of deaths
occurred during the follow-up period (13 years) of the
1990e1994 birth cohort that it was deemed appropriate to
combine the 1985e1989 and 1990e1994 birth cohorts. Subse-
quently, birth cohort lifetables were calculated and survivorship
curves generated for each country, for one 5-year and one 10-year
birth cohort (1980e1984, 1985e1994) using the KaplaneMeier
method (SURV and SURVFIT functions) in R software version
2$10$1 (downloadable from http://www.r-project.org/).
14
Although less than 50% of the CFRI 1980e1984 birth cohort
had died by 2007, the observed median survival could be deter-
mined using the KaplaneMeier method. The point in time to
which 50% of the cohort survives is not necessarily the same as
the median for the KaplaneMeier derived cumulative survival
function. This can occur when a lifetable contains censored
observations prior to the 50th percentile of the cumulative
survival function.
ANALYSIS STRATEGY
Various parametric models were used to ﬁt survival curves for
birth cohort lifetable predicted median survival estimation.
Because of its large size, the pooled US CFF birth cohort dataset
(1980e1994) was used to select the best ﬁtting parametric
survival model. Model parameters were then estimated for the
US dataset using the variables gender and birth cohort
(1980e1984, 1985e1994). The model structure that best ﬁt the
US dataset was applied to the CFRI dataset in order to evaluate
the ability of the model to estimate birth cohort lifetable
predicted median survival. Model parameters were calculated
independently for the CFRI dataset.
INTRODUCTION TO MODEL DEVELOPMENT
A parametric model assumes that observed data follows
a particular distribution (eg, exponential, Weibull) and that one
of those different distributions will best ﬁt CF survival data.
Unlike non-parametric models (eg, Cox proportional hazards),
extrapolation of survival estimates beyond the study observa-
tion period is possible using a parametric approach.
15 However,
the beneﬁt of projecting a survival estimate beyond observed
data is tempered by the sensitivity of the estimate (and its
associated degrees of uncertainty) to the underlying model
structure and is governed by the size and duration of follow-up
of the observed birth cohort.
Patients with CF who died before their ﬁrst birthday were
excluded during model development because high mortality
Table 1 Characteristics of patients born between 1980 and 1994
enrolled on the US Cystic Fibrosis Foundation Patient Registry and the
Cystic Fibrosis Registry of Ireland, with known vital status, and who








Patients with CF, 1980e1994 birth
cohorts
13164 659
Gender: male 6730 (51.1%) 354 (53.7%)
Birth cohort deaths by 2007 2290 199
Deaths in under 1 year olds 50 35
Person-years of follow-up 248995.6 11728.0
Deaths per 10000 person-years 92.0 169.7
Table 2 Deaths observed by 2007 for three 5-year birth cohorts
(1980e1984, 1985e1989, 1990e1994) of patients enrolled on the US
Cystic Fibrosis Foundation Patient Registry and the Cystic Fibrosis
Registry of Ireland
US Cystic Fibrosis Foundation
Patient Registry
Cystic Fibrosis Registry of
Ireland
Birth cohort (N) Deaths (%) Birth cohort (N) Deaths (%)
1980e1984 4070 32 261 47.9
1985e1989 4510 15.6 228 21.5
1990e1994 4584 6.2 170 14.7
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Cystic ﬁbrosisrates during the ﬁrst year of life led to poor model ﬁt. Addi-
tionally, this action unintentionally beneﬁtted the analysis
because potential bias introduced by the unavoidable omission
of unrecognised infant deaths from CFF
3 16 and CFRI datasets
was avoided. The parametric model and the corresponding birth
cohort lifetable predicted median survival estimates are for
patients with CF surviving their ﬁrst birthday.
Model parameter estimation, which was performed indepen-
dently for CFF and CFRI datasets, involved adding gender and
birth cohort (1980e1984, 1985e1994) as potential explanatory
variables to the model. Differences between the two cohorts and
between male and female survival estimates were examined
(table 3). Fully separated models (stratiﬁed by both gender and
birth cohort) were excluded from the analysis a priori because of
the small proportion of deaths observed in US male patients
born between 1985 and 1994 (9%) and US female patients born
between 1985 and 1994 (12%). Parametric model ﬁtting and
parameter estimation was performed using the SURVREG
function in R.
MODEL SELECTION AND FITTING USING US CF FOUNDATION
PATIENT REGISTRY DATA
Four model structures, each with a distinct underlying survi-
vorship function for ﬁtting observed data to parametric models,
were deemed suitable for examination: exponential, Weibull, log-
logistic and log-normal. Initially, all US CFF data were entered
into the model, pooling observations across birth cohorts
(1980e1994) and gender to help decide which model structure
was most appropriate for the data (table 3, model A).
Akaike’s Information Criterion (AIC) was used to determine
which underlying model best ﬁtted observed survivorship, with
lower values indicating a better ﬁt. Because log-likelihood is an
additive property of a model and dataset,
17 AIC values can be
summed across non-overlapping stratiﬁcations of the same
dataset to yield an overall AIC value for the entire dataset.
18
Birth cohort lifetable predicted median survival and 95% CIs
were estimated using the SURVREG function reverse prediction
method.
14
Using the pooled US dataset (1980e1994) of patients with CF
surviving their ﬁrst birthday (13115 observations), the Weibull
(AIC ¼24060.3) model best explained the data (ﬁgure 1, table 3).
On examining differences in survivorship between gender and
birth cohorts, the best model contained gender and birth cohort
(1980e1984, 1985e1994) as the main effects under a Weibull
distribution (table 3, model D), and was marginally better than
the model containing gender and birth cohort with an interac-
tion effect (model E).
Under the model with main effects of gender and birth cohort,
US male patients were shown to live longer than female patients
and survival improved between the 1980e1984 and 1985e1994
birth cohorts (ﬁgure 2A, table 4). Birth cohort lifetable predicted
median survival for patients surviving their ﬁrst birthday was
37.8 and 31.5 years for male and female patients born between
1980 and 1984, and 50.9 years and 42.4 years for male and
female patients born between 1985 and 1994.
PARAMETER FITTING USING CFRI DATA
Because the Weibull model was deemed to best ﬁt US CFF
survivorship data, the model was applied to the CFRI dataset.
Estimation of CFRI model parameters took place independently
of the CFF model parameter estimation. A dataset of 624 CFRI
patients with CF born between 1980 and 1994 and surviving
their ﬁrst birthday was entered into the model. An AIC of 1659
was determined for the null Weibull model (ie, no explanatory
factors were used in the model). Inclusion of explanatory factors
improved model ﬁt and a Weibull model containing gender and
birth cohort as the main effects was the best ﬁtting (AIC¼1633).
Birth cohort lifetable predicted median survival estimates for
male and female patients surviving their ﬁrst birthday were 32.3
and 24.7 years respectively for those born between 1980 and
1984, and 51.1 and 39.0 years for those born between 1985 and
1994 (ﬁgure 2B, table 5). Predicted median survival estimates
increased between the birth cohorts by 18.8 years for male
patients and 14.3 years for female patients.
COMPARISON OF CFRI BIRTH COHORT LIFETABLE OBSERVED
(KAPLANeMEIER) AND PREDICTED MEDIAN SURVIVAL
ESTIMATES
While birth cohort lifetable predicted median survival estimates
were calculated for both CFF and CFRI study populations, the
Table 3 Akaike Information Criteria (AIC) for Weibull models with
explanatory variables of gender and birth cohort (1980e1984 and
1985e1994) for patients enrolled on the US Cystic Fibrosis Foundation






A Null (no variables) 24302.8
B Gender 24232.1
C Birth cohort 24128.7
D Gender and birth cohort as main effects 24060.3
E Gender and birth cohort with interaction 24062.2
F Separated models for gender 24232.4
Male 10828.4
Female 13404.0
G Separated models for birth cohort 24108.3
1980e1984 13000.1
1985e1994 11108.2
Figure 1 KaplaneMeier survivorship curve and parametric models
with associated Akaike Information Criteria for patients born between
1980 and 1994 enrolled on the US Cystic Fibrosis Foundation Patient
Registry who survived their ﬁrst birthday.
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Cystic ﬁbrosislatter dataset allowed an evaluation of the ability of the para-
metric model to predict birth cohort lifetable observed median
survival. A birth cohort lifetable observed median survival esti-
mate was derived for CFRI patients with CF born between 1980
and 1984 and surviving their ﬁrst birthday using the
KaplaneMeier method (see Study data). Model-estimated birth
cohort lifetable predicted median survival was compared with
the actual observed (KaplaneMeier) median survival to deter-
mine whether the selected model was capable of reliably esti-
mating predicted median survival. A full evaluation of the
suitability of the model for estimating survival will only be
possible once a dataset becomes available which has followed all
patients in a birth cohort until death.
As the actual (KaplaneMeier) median survival of the CFRI
1980e1984 birth cohort was observed for male patients, but not
female patients, the comparison of model-predicted and
observed median survival estimates required male and female
birth cohort datasets to be pooled. A Weibull model was applied
to the CFRI 1980e1984 birth cohort consisting of 243 patients
with CF surviving their ﬁrst birthday (cf, table 3, model G:
1980e1984). The performance of the model in predicting
median survival after short duration of follow-up was examined
by censoring observed survivorship data (ﬁgure 3). Initially,
survivorship data were censored after 5 years; therefore only
follow-up data to the 31 December 1989 were used in the model.
A birth cohort lifetable predicted median survival of 40.0 years
was estimated based on only 5 years of follow-up.
The follow-up period was then extended a year at a time until
2007. A new model was developed each time and model-
predicted median survival was re-estimated on each occasion.
Convergence of the birth cohort lifetable predicted to the
observed median survival estimate (for patients with CF
surviving their ﬁrst birthday) of 27.7 years (lower 95% CI: 24.8,
upper 95% CI: indeterminate) was good, particularly from 1995
onwards, which corresponds to 20% observed mortality in the
1980e1984 birth cohort.
Figure 2 KaplaneMeier survivorship
curves (females ¼ B, males ¼ Δ) with
ﬁtted Weibull model with main effects
of gender (female ¼ black line, male ¼
red line) and birth cohort and
corresponding 95% CIs (dashed lines)
for patients with cystic ﬁbrosis
surviving their ﬁrst birthday and enrolled
on the US Cystic Fibrosis Foundation
Patient Registry (A) and the Cystic
Fibrosis Registry of Ireland (B).
Table 4 Birth cohort lifetable predicted median survival estimates and
95% CIs for a Weibull model with main effects of gender and birth cohort
for patients enrolled on the US Cystic Fibrosis Foundation Patient
Registry surviving their ﬁrst birthday
Gender and birth cohort
Median survival estimate
in years (95% CI)
Male births 1980e1984 37.8 (36.2 to 39.3)
Female births 1980e1984 31.5 (30.4 to 32.6)
Male births 1985e1994 50.9 (48.0 to 53.8)
Female births 1985e1994 42.4 (40.2 to 44.5)
Table 5 Birth cohort lifetable predicted median survival estimates and
95% CIs for a Weibull model with main effects of gender and birth cohort
for patients enrolled on the Cystic Fibrosis Registry of Ireland surviving
their ﬁrst birthday
Gender and birth cohort
Median survival estimate
in years (95% CI)
Male births 1980e1984 32.3 (27.1 to 37.5)
Female births 1980e1984 24.7 (21.3 to 28.1)
Male births 1985e1994 51.1 (38.8 to 63.3)
Female births 1985e1994 39.0 (30.8 to 47.1)
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Cystic ﬁbrosisDISCUSSION
By developing parametric models of CF birth cohort data to
project survivorship, we have started to overcome the challenge
of median survival estimation associated with short duration of
follow-up of recent cohorts. This approach is suited to survival
estimation for disorders where better treatment has resulted in
continued improvement in survivorship. Although limitations
remain when estimating survival in rare disease populations,
regardless of methodological approach,
9 we have shown that our
model can be applied to registry datasets of variable size,
demonstrating its utility as a tool to estimate survival at a local
level.
Better treatment has resulted in continued improvement in
CF survival, particularly in childhood, yet the current lifetable
method, which applies static age-speciﬁc mortality rates to
a hypothetical population in order to project estimates of life
expectancy, is favoured by CF registries. At best, annual median
predicted CF survival estimates derived by current lifetables can
only provide a snapshot of a moving target.
13 For conditions
with ﬂuctuating age-speciﬁc mortality rates, longitudinal tech-
niques, that is, birth cohort lifetables, may be more appropriate
for monitoring survival. However, prospective follow-up of birth
cohorts by many CF registries has not yet yielded an observed
median survival. Birth cohort follow-up can be undertaken
retrospectively and although limitations to this approach exist,
using registered death information to supplement registry data
reduces the probability of positively biasing survival estimates,
and allows parametric modelling to proceed.
One advantage of predicting birth cohort median survival is
that median survival can be estimated by gender and year of
birth. Therefore, counselling parents of newly diagnosed
patients on the prospect of their child’s survival can be appro-
priately tailored. This is an improvement on current lifetable
estimates, which are typically reported for an entire registry
population. For example, the US CFF reported a current lifetable
median survival estimate of 37.4 years in 2008,
3 whereas model-
derived birth cohort median predicted survival estimates suggest
that US male and female patients born between 1985 and 1994
and surviving their ﬁrst birthday live a median of 50.9 and
42.4 years respectively. As in others studies of CF survival which
considered gender and birth cohort as explanatory factors, this
study found that the period effect was the strongest determi-
nant of survival into adulthood.
19 Second, clinical management
of patients with CF is complex and the survival beneﬁt from
novel therapies, early diagnosis and specialist, multi-disciplinary
care remain unclear. Projecting birth cohort survivorship beyond
the treatment period using a parametric approach could provide
better insights into the effectiveness of current clinical practices.
A comparison of model estimates of median predicted survival
between the 1980e1984 and 1985e1994 birth cohorts reafﬁrms
that CF survival is improving in both the USA and Ireland. As in
other studies, a gender gap in CF survival can be observed,
20 21
however data comparing observed survival by gender across
sequential birth cohorts are not often published,
52 22 3making it
difﬁcult to interpret our ﬁndings.
Differences in median survival estimates appear to exist
internationally in this study and other studies.
23 In addition to
factors such as variability in diagnostic practices, genotype
distribution and patient and transplantation management
strategies between countries,
24e26 the methodological approach
used to estimate survival should be considered as a possible
source of discordance during international survival estimate
comparison. Cross-sectional comparison (ie, at a given time
point) of international median predicted survival estimates
derived using current lifetables has been shown to be
misleading.
27 Comparison of median age at death estimates
derived from decedent CF populations has also been under-
taken,
24 but this measure of survival is considered unsatisfactory
because it underestimates the observed median survival derived
from following an entire CF population.
27 Although this study
has shown that parametric models can be ﬁtted to registry
datasets to derive estimates of median predicted survival,
registry information has inherent limitations that can affect the
reliability of model-derived survival estimates.
CF registries acknowledge that their datasets are not entirely
representative of the CF population, and report population
coverage levels of approximately 90%.
20 28 Because patient
consent is required for registry enrolment, registries are often
unable to observe those who died before being invited to enrol,
those opting not to participate, and others yet to be identiﬁed by
the registry. To avoid the introduction of bias into birth cohort
lifetables, all affected people need to be included. Differences in
median survival estimates may be partly explained by potential
biases in data collection by CF registries. Unlike the US datasets,
national mortality records were included in the Irish birth cohort
datasets, although deceased patients with CF in Ireland may not
have been identiﬁed if CF was not reported as the underlying
cause of death (eg, trauma, suicide), but rather a factor
contributing to death. The omission of unrecognised deceased
patients with CF from the US CFF Patient Registry prior to
1986, particularly childhood mortality data, which are not
insubstantial,
16 may have resulted in US survival estimates
being positively biased. Although the large size of the US data-
sets allows more precise estimates of birth cohort lifetable
predicted median survival to be derived, the effect of bias on
survival estimation is not reduced.
Although the inclusion of additional explanatory variables
(potentially available for prospectively followed birth cohorts)
Figure 3 Median predicted survival and 95% CIs for patients born
between 1980 and 1984 enrolled on the Cystic Fibrosis Registry of
Ireland and surviving their ﬁrst birthday, estimated under a Weibull
model during a 23-year follow-up period, in which follow-up was
censored in each calendar year. The actual (KaplaneMeier) median
survival for patients with cystic ﬁbrosis surviving their ﬁrst birthday
observed at the study end point (2007) is also shown.
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Cystic ﬁbrosiscould further reﬁne the predictive ability of this model, this was
not possible for the analysis of the Irish data. Instead, our aim
was to examine whether survival estimates could be projected
beyond observed follow-up data in the ﬁrst instance and identify
a suitable model structure which could potentially be adopted
by others.
Estimates of survival are important for planning service
requirements and evaluating interventions, but in reality, how
long any newborn baby with CF will live cannot be known. As
with any model projecting survival estimates beyond observed
data, population ascertainment, size and duration of follow-up of
observed data affect the sensitivity of our model. When observed
and predicted birth cohort lifetable median survival estimates
were examined for our validation cohort, we found that esti-
mates were comparable but also that the model was valid in
a population smaller than that used to develop the model.
In conclusion, parametric models of birth cohorts can over-
come the challenge of estimating birth cohort lifetable predicted
median survival following a short follow-up period for a disorder
experiencing continued improvement in survivorship. This
approach may provide better opportunities to monitor survival
and plan CF services at the local level.
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